FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Orphan Status news from FierceBiotech

News

Osiris sells stem cell business to NuVasive

Medical device maker NuVasive is buying Osteocel, Osiris' biologics business, for $35 million up front and an additional $50 million in milestone payments. The Osteocel business includes an adult Read more...

Pharming shares sink after Rhucin gets thumbs down

There's new trouble for Pharming's Rhucin, an experimental treatment for hereditary angioedema. Pharming shares plunged after the company announced that the EMEA's Committee for Medicinal Products Read more...

ChemGenex restructures, focuses on cancer drugs

ChemGenex Pharmaceuticals, which recently reported positive data on the experimental leukemia therapy Ceflatonin, says it is restructuring the company so it can focus on its cancer therapies. The Read more...

Pharming raises $99M

Netherlands-based Pharming has raised $99 million (€70 million) through the issue of convertible bonds. The issue was managed by UBS Investment Bank. The company is also finalizing discussions for Read more...

Aspreva, Roche put CellCept on ice

Shares of Aspreva Pharmaceuticals slipped a bit this morning after the company and Roche announced that they would not be pushing ahead with a regulatory filing for CellCept, a new therapy for lupus Read more...

Pharming says it's closing in on Rhucin approval

Pharming says that the positive interim results it has received from a study of Rhucin is blazing the way to EMEA approval. The Amsterdam-based developer says it expects EMEA approval in the fourth Read more...

Chelsea wins European orphan status

European drug regulators granted orphan drug status to Chelsea Therapeutics' remedy for hypotension, Droxidopa, and recommended the same for Progen's experimental liver drug, known as PI-88. Designed Read more...

Regulators focusing on transgenic animals

Genetically engineered animals are producing a range of therapies for human use, and The New York Times catches up on the action at companies like Read more...